S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH‐RISK CYTOGENETIC ABNORMALITIES
Stephan A. Grupp(Children's Hospital of Philadelphia), Michael A. Pulsipher(Primary Children's Hospital), Stephen P. Hunger(Children's Hospital of Philadelphia), Susana Rives(Hospital Sant Joan de Déu Barcelona), Cord Peters(St Anna Children's Hospital), Simon Davies(Cincinnati Children's Hospital Medical Center), Peter Bader(Goethe University Frankfurt), Eneida R. Nemecek(Oregon Health & Science University), Muna Qayed(Emory University), Lamis Eldjerou, A. Chassot Agostinho(Novartis (Switzerland)), Shannon L. Maude(Children's Hospital of Philadelphia), Ranjan Tiwari(Novartis (India)), Joerg Krueger(Hospital for Sick Children), Santhi D. Konduri(University of Central Florida), Nicolas Boissel(Inserm), Michael Boyer(Chris O’Brien Lifehouse), Theodore W. Laetsch(Children's Hospital of Philadelphia), Timothy Driscoll(Institut Pasteur), Jason Levine(Icahn School of Medicine at Mount Sinai), André Baruchel(Hôpital Robert-Debré), Greg Yanik(Michigan Medicine), K. S. Davis(Stanford University), Gary Douglas Myers(Baylor College of Medicine)
Cited by 2
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k